Slide 1: Accelerating AstraZeneca's strategic and financial development
Connection details https://astrazeneca.zoom.us/s/99546038702 +44 203 481 5237 +46 8 5052 0017 +1 301 715 8592 ID: 995 4603 8702 | PW: 12121220 Accelerating AstraZeneca’s strategic and financial development AstraZeneca to acquire Alexion 12 December 2020 This webinar and conference call for investors
Slide 2: Forward-looking statements
Forward-looking statements This document may include statements that are or may be deemed to be forward-looking statements. These forward-looking statements may be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "envisages", "plans", "projects", "an
Slide 3: Disclaimer
Disclaimer Important additional information Neither this presentation nor any copy of it may be taken or transmitted directly or indirectly into or from any jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction. Any failure to comply with t
Slide 4: AstraZeneca's transformation has been pipeline-led
AstraZeneca’s transformation has been pipeline-led Broad presence Strong pipeline Improving financials Balanced specialty and 17 Phase III medicines and Nine blockbuster medicines primary-care franchises1 significant lifecycle projects Returned to sustainable Leading emerging markets Advancing early
Slide 5: AstraZeneca has been expanding its Immunology effort
AstraZeneca has been expanding its Immunology effort Focus on achieving leadership in diseases driven by IFN, eosinophilia and epithelial injury across Rheumatology, Dermatology and Gastroenterology 1 Near-term 2 Medium-term 3 Long-term Anifrolumab in SLE Strengthen Rheumatology, enter Cement our po
Slide 6: Alexion is aligned with our strategy
Alexion is aligned with our strategy Our external growth strategy is anchored in clear principles Aligns with AstraZeneca’s strategy − Deliver therapy area leadership − Accelerate innovative science AstraZeneca adding value through therapy-area leadership, scientific complementarity, and/or geograph
Slide 7: Alexion is a global leader in immune-mediated rare diseases
Scientific leadership Shared purpose and values Industry-leading growth Strong financials Alexion is a global leader in immune-mediated rare diseases1 Alexion: market-leading complement Successful commercial execution Robust pipeline across immune- franchise Revenue CAGR 20% 2017-2020 LTM mediated a
Slide 8: Alexion: a pioneer innovator in C5 complement inhibition
Scientific leadership Shared purpose and values Industry-leading growth Strong financials Alexion: a pioneer innovator in C5 complement inhibition Bringing life-saving medicines to more patients Ultomiris has achieved impressive ~70% conversion in 18 months in PNH across key geographies (US, JP, DE)
Slide 9: Alexion: accelerating AZ's strategic and financial development
Scientific leadership Shared purpose and values Industry-leading growth Strong financials Alexion: accelerating AZ’s strategic and financial development Compelling scientific complementarity and synergy › Increased immunology presence: complement system research platform, currently applied in rare d
Slide 10: Combined R&D capabilities cover both adaptive & innate immunity
Scientific leadership Shared purpose and values Industry-leading growth Strong financials Combined R&D capabilities cover both adaptive & innate immunity Improved ability to identify attractive new targets Adaptive Immunity Innate Immunity Humoral Cell Mediated Lectin Classical Alternative Type 1 Ty
Slide 11: Complement system research platform applicable in many diseases
Scientific leadership Shared purpose and values Industry-leading growth Strong financials Complement system research platform applicable in many diseases Complement technology platform Therapeutic areas Rare diseases Common diseases Oncology* Glioblastoma Lung Renal Breast Gastric NHL Prostate Haema
Slide 12: Convergence of two patient-centric care deliveries
Scientific leadership Shared purpose and values Industry-leading growth Strong financials Convergence of two patient-centric care deliveries Scientific platforms supporting complementary development and commercial channels Common Diseases Less Common Diseases Rare Diseases Prescribers GPs / PCPs Spe
Slide 13: Strong C5 franchise, and a number of innovative assets
Scientific leadership Shared purpose and values Industry-leading growth Strong financials Strong C5 franchise, and a number of innovative assets Market-leading and highly durable C5 franchise (Soliris / Ultomiris) › Proven impressive product conversion expertise; next generation innovative C5 formul
Slide 14: Complementary cultures with shared focus on patients
Scientific leadership Shared purpose and values Industry-leading growth Strong financials Complementary cultures with shared focus on patients • Two companies with shared mission and purpose – to create value for patients through delivery of innovative medicines › Opportunity for shared learnings an
Slide 15: A new pure-play biopharma innovator
Scientific leadership Shared purpose and values Industry-leading growth Strong financials A new pure-play biopharma innovator with strong profitability, and industry-leading science and growth Broad Presence Strong Pipeline Superior Financials Leading commercial infrastructure Scientific leadership
Slide 16: Stronger innovative portfolio to drive sustainable growth
Scientific leadership Shared purpose and values Industry-leading growth Strong financials Stronger innovative portfolio to drive sustainable growth Oncology Rare diseases CVRM5, R&I - Organ protection and $10.8bn | +17%1 $5.9bn | +24%3 immune-mediated diseases $10.0bn | +5%6 • Lung, ovarian, breast,
Slide 17: The combination cements AstraZeneca's growth leadership
Scientific leadership Shared purpose and values Industry-leading growth Strong financials The combination cements AstraZeneca’s growth leadership AZ double-digit revenue growth AstraZeneca vs. sector peers revenue CAGR (2021E-2024E) 6.6% 4.7% 4.1% Median of Peers: 3.6% 3.6% 3.6% 3.5% 3.3% 3.2% 3.0%
Slide 18: Rare diseases is a strong growth driver
Scientific leadership Shared purpose and values Industry-leading growth Strong financials Rare diseases is a strong growth driver Accelerating growth and innovation in an area of high unmet needs Rare diseases are a significant Worldwide rare disease Worldwide sales growth by burden to global public
Slide 19: Strengthening US presence and leveraging global footprint
Scientific leadership Shared purpose and values Industry-leading growth Strong financials Strengthening US presence and leveraging global footprint AstraZeneca Combined company Alexion Other EM EM 13% RoW US 33% Other EM 9% 4% Japan 21% China 9% 12% 4% US 59% RoW 10% 19% 38% US 19% China 17% Europe
Slide 20: Integration provides enhanced US and global presence
Scientific leadership Shared purpose and values Industry-leading growth Strong financials Integration provides enhanced US and global presence AstraZeneca Global with large presence in emerging markets R&D in Cambridge, Gothenburg and Gaithersburg ( ) with satellite R&D in Boston Provides greater pl
Slide 21: Attractive financial profile with strong revenue growth
Scientific leadership Shared purpose and values Industry-leading growth Strong financials Attractive financial profile with strong revenue growth Pro-forma financials (last twelve months1) 10% 32% Revenue growth Core operating profit margin $32bn $11bn $28bn Revenue EBITDA Net debt2 Source: Pro-form
Slide 22: Capital-allocation priorities
Scientific leadership Shared purpose and values Industry-leading growth Strong financials Capital-allocation priorities Alexion supports value creation Immediately earnings- Investment in accretive, value-enhancing the business opportunities Maintaining a strong, Supporting the investment-grade prog
Slide 23: Details and timeline: Anticipated closing in Q3 2021
Details and timeline Anticipated closing in Q3 2021 Proposed key terms Anticipated timeline • Price $175 per share of Alexion • Following anticipated closing in Q3 2021, Alexion shareholders will own ~15% of the combined company • Each shareholder of Alexion will receive • $60 in cash • Transaction
Slide 24: Alexion: accelerating AZ's strategic and financial development
Scientific leadership Shared purpose and values Industry-leading growth Strong financials Alexion: accelerating AZ’s strategic and financial development Compelling scientific complementarity and synergy › Increased immunology presence: complement system research platform, currently applied in rare d
Slide 25: Q&A
Q&A
Slide 26: Growth sustainability underpinned by longevity beyond 2030
Growth sustainability underpinned by longevity beyond 2030 2025 2030 2035 Ultomiris Tezepelumab ** DS-8201 * AKT Inhibitor monalizumab * Lokelma Tagrisso Calquence Imfinzi * Oncology Breztri CVRM Kanuma PT027 Respiratory & Immunology Fasenra ** Rare disease Strensiq Lynparza * Soliris 1 Farxiga Bydu